Your browser doesn't support javascript.
loading
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
Chu, Laurence; McPhee, Roderick; Huang, Wenmei; Bennett, Hamilton; Pajon, Rolando; Nestorova, Biliana; Leav, Brett.
  • Chu L; Benchmark Research, 3100 Red River St #2, Austin, TX 78705, United States.
  • McPhee R; Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States.
  • Huang W; Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States.
  • Bennett H; Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States.
  • Pajon R; Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States.
  • Nestorova B; Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States.
  • Leav B; Moderna, Inc., 200 Technology Sq, Cambridge, MA 02139, United States. Electronic address: brett.leav@modernatx.com.
Vaccine ; 39(20): 2791-2799, 2021 05 12.
Article en En | MEDLINE | ID: mdl-33707061
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Año: 2021 Tipo del documento: Article